

ASX / Media Release

17 November 2010

Resonance Health Announces new FerriScan[®] contracts

Following the execution of a 3-year Master Service Agreement with Novartis AG (Basel, Switzerland) and Novartis Pharmaceutical Corporation (U.S.), announced in October this year, Resonance Health today announces the execution of the first contracts under the Agreement, for a value of over US\$600,000.

The services are for immediate commencement and involve the provision of FerriScan to many countries.

The growing international acceptance of the value of FerriScan has seen a 100% increase in US facilities, now totalling 28 centres in the US alone, using FerriScan for the management of their patients with iron overload disorders this year.

The Company will be exhibiting FerriScan at the American Society of Hematology (ASH) meeting in the US next month. This event is the premier international event for Hematology and is attended by over 20,000 medical professions and industry participants, providing an excellent opportunity for the Company to reach a large audience.

By Order of the Board
Resonance Health Limited

For further information please contact:

Resonance Health

Liza Dunne
Managing Director
T: +61 8 9286 5300
E: lizad@resonancehealth.com

Stewart Washer
Chairman
T: +61 8 9286 5300
E: sjwasher@bigpond.com

Resonance Health Ltd (ASX: RHT) (www.resonancehealth.com) is a medical device company providing core laboratory services utilising advanced technology for the analysis of medical images. Its patented technology FerriScan[®] provides a safe and accurate method for measuring liver iron concentration (LIC), a significant issue for patients with iron overload.